In ovarian cancer, where it has been dissected the role of β-arr in ET-1 signaling, in vivo, silencing of β-arr1 or macitentan treatment, impairing the signaling pathways involved in cell survival, EMT, and invasion, reduces tumor growth, vascularization, intravasation, and metastatic progression, and potentiates the cytotoxic effects of cisplatinum [15, 16]. This evidence concerns the gene EDN1 and ovarian carcinoma.